The UK FemTech Startups Finally Giving Menopause The Attention It Deserves

Menopause affects around half the global population. It’s not included among the NIH’s approximately 300 research categories. Global productivity losses attributed to menopause symptoms are estimated at $150 billion a year. And for most of the history of modern medicine, the products and services available to women navigating it have been insufficient.

The momentum is building – and UK femtech is leading the change. The UK’s women’s health technology sector has attracted more than £480 million in investment and is growing at 30% annually, according to analysis by Grant Thornton. Forty-five percent of all European menopause startups are UK-based, according to Sifted. In April 2026, the UK government launched a refreshed Women’s Health Strategy alongside a £1.5 million femtech challenge fund specifically designed to accelerate innovation in the sector. The momentum is undeniable, and 2026 is starting to feel like the year it tips into something permanent.

The global appetite for this category is visible beyond the UK too. Irish startup Peri – formerly identifyHer – launched a menopause wearable at CES 2025 and began taking orders at CES 2026, tracking physiological signals including temperature, EDA and motion to deliver AI-generated insights on hot flashes, night sweats and anxiety. The product attracted significant attention, an indicator of how much unmet demand exists in this space even before you get to the UK startups building in it.

The UK Startups Building What The Healthcare System Missed

Vira Health is one of the most established UK names in menopause technology. Its Stella app takes a non-hormonal approach to hot flush management, combining cognitive behavioural therapy techniques with AI-driven tracking.For women who are unable or unwilling to pursue hormone replacement therapy, a clinically validated, digital-first solution represents a significant departure from the limited options of the past.

Menopause is a major pillar of UK femtech, but it’s just one part of a diversifying market. The category covers reproductive health, fertility, pregnancy, postpartum care, sexual health and the full arc of hormonal health across a lifetime. What unites the most interesting companies in the space is a recognition that women’s health has been systematically under-researched – not because the demand wasn’t there, but because the funding and attention wasn’t directed at it.

Globally, femtech raised $72 million in March 2026 alone, with menopause solutions described by sector analysts as one of the hottest areas within the category. This is capital arriving late into a market that was always there.

Why 2026 Feels Different

While the capital is essential, the accompanying policy shifts carry equal weight in driving real change.
The UK government’s Women’s Health Strategy, refreshed with dedicated femtech funding, indicates that the regulatory and procurement environment is moving towards supporting innovation rather than ignoring it. For startups in the women’s health space, government validation is the gatekeeper, dictating whether a product remains a niche consumer offering or ascends to the level of clinical integration.

The demographic pressure is also building. The global population of women over 50 – the primary demographic for menopause products – is growing, this generation is more informed, more vocal, and significantly less likely to accept substandard care than those who came before them. The cultural shift and the market opportunity are moving in the same direction at the same time.

For UK femtech, the combination of investment momentum, government backing, European market leadership and a generation of women who are actively seeking better solutions creates a rare alignment. The research gap that left menopause off the NIH’s priority list for decades is a problem that technology can’t entirely fix – but it can build around it, and the UK is doing exactly that.